Your browser doesn't support javascript.
loading
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group.
Leahy, Joy; Hickey, Conor; McConnell, David; Cassidy, Owen; Trela-Larsen, Lea; Barry, Michael; Tilson, Lesley; McCullagh, Laura.
Afiliación
  • Leahy J; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland. Electronic address: jleahy@stjames.ie.
  • Hickey C; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
  • McConnell D; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
  • Cassidy O; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
  • Trela-Larsen L; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
  • Barry M; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
  • Tilson L; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
  • McCullagh L; National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
Value Health ; 23(11): 1423-1426, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33127011
ABSTRACT
It is expected that the coronavirus disease 2019 (COVID-19) pandemic will leave large deficits in the budgets of many jurisdictions. Funding for other treatments, in particular new treatments, may become more constrained than previously expected. Therefore, a robust health technology assessment (HTA) system is vital. Many clinical trials carried out during the pandemic may have been temporarily halted, while others may have had to change their protocols. Even trials that continue as normal may experience external changes as other aspects of the healthcare service may not be available to the patients in the trial, or the patients themselves may contract COVID-19. Consequently, many limitations are likely to arise in the provision of robust HTAs, which could have profound consequences on the availability of new treatments. Therefore, the National Centre for Pharmacoeconomics Review Group wishes to discuss these issues and make recommendations for applicants submitting to HTA agencies, in ample time for these HTAs to be prepared and assessed. We discuss how the pandemic may affect the estimation of the treatment effect, costs, life-years, utilities, discontinuation rates, and methods of evidence synthesis and extrapolation. In particular, we note that trials conducted during the pandemic will be subject to a higher degree of uncertainty than before. It is vital that applicants clearly identify any parameters that may be affected by the pandemic. These parameters will require considerably more scenario and sensitivity analyses to account for this increase in uncertainty.
Asunto(s)
Texto completo: Disponible Colección: Bases de datos internacionales Contexto en salud: Agenda de Salud Sostenible para las Américas Tema en salud: Objetivo 4: Financiamiento de la salud / Objetivo 5: Medicamentos, vacunas y tecnologías sanitarias Base de datos: MEDLINE Asunto principal: Neumonía Viral / Evaluación de la Tecnología Biomédica / Infecciones por Coronavirus / Comités Consultivos / Pandemias Tipo de estudio: Ensayo clínico controlado / Evaluación económica en salud / Evaluación de tecnologías sanitárias / Patient_preference Aspecto: Preferencia del paciente Límite: Humanos Idioma: Inglés Revista: Value Health Asunto de la revista: Farmacología Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Colección: Bases de datos internacionales Contexto en salud: Agenda de Salud Sostenible para las Américas Tema en salud: Objetivo 4: Financiamiento de la salud / Objetivo 5: Medicamentos, vacunas y tecnologías sanitarias Base de datos: MEDLINE Asunto principal: Neumonía Viral / Evaluación de la Tecnología Biomédica / Infecciones por Coronavirus / Comités Consultivos / Pandemias Tipo de estudio: Ensayo clínico controlado / Evaluación económica en salud / Evaluación de tecnologías sanitárias / Patient_preference Aspecto: Preferencia del paciente Límite: Humanos Idioma: Inglés Revista: Value Health Asunto de la revista: Farmacología Año: 2020 Tipo del documento: Artículo